Ipsen’s partner Exelixis announces clinical collaboration with Bristol Myers Squibb for late-stage combination trial in first-line renal cell carcinoma.

Full year 2018 results conference call

Ipsen reiterated its commitment to the Innobio-2 fund

Ipsen commits to making all its published scientific research freely accessible to everyone

Ipsen announces 50 posters to be presented at the 2019 TOXINS Congress – January 16-19